A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health
Phase of Trial: Phase I
Latest Information Update: 30 May 2017
At a glance
- Drugs JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Janssen
- 23 May 2017 Planned primary completion date changed from 15 Mar 2019 to 22 Feb 2018.
- 02 Dec 2016 Status changed from not yet recruiting to recruiting.
- 13 Oct 2016 New trial record